Journal Article
. 2015 May; 3(9):1008-16.
doi: 10.1158/2326-6066.CIR-14-0227.

Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab

Serena S Kwek 1 Jera Lewis 1 Li Zhang 2 Vivian Weinberg 3 Samantha K Greaney 1 Andrea L Harzstark 1 Amy M Lin 1 Charles J Ryan 2 Eric J Small 2 Lawrence Fong 4 
Affiliations
  • PMID: 25968455
  •     22 References
  •     31 citations

Abstract

Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockade can induce tumor regression and improved survival in cancer patients. This treatment can enhance adaptive immune responses without an exogenous vaccine, but the immunologic biomarkers associated with improved clinical outcome in cancer patients are not fully established. A phase Ib trial in patients with metastatic, castration-resistant prostate cancer was performed combining ipilimumab with sargramostim (GM-CSF). In addition to evaluating ipilimumab dose, patients were followed clinically for response and overall survival, and for immunomodulation of circulating T cells. PSA declines of ≥50% and radiographic responses were observed at doses of ≥3 mg/kg/dose. Timing of clinical responses could be either immediate or delayed. Durable responses were also observed off treatment. A subset of patients experienced long-term survival with or without objective clinical responses. The relationship between T-cell phenotype in peripheral blood and overall survival was examined retrospectively. We found that the treatment induced an increase in the levels of CD4(+) effector T (Teff) cells, regulatory T cells, PD-1(+) CD4 Teff cells, and PD-1(+) CD8 T cells. However, these increased levels were not associated with overall survival. Instead, low pretreatment baseline levels of PD-1(+) CD4 Teff cells were found to correlate with longer overall survival. Furthermore, baseline levels of PD-1(+) CD4 Teff cells from patients with shorter overall survival were higher than from cancer-free male control subjects. These results suggest that preexisting expression of immunologic checkpoint marker PD-1 on CD4 Teff cells may help identify patients that may benefit from ipilimumab treatment.

Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Search for diphoton events with large missing transverse energy in 7 TeV proton-proton collisions with the ATLAS detector.
G Aad, B Abbott, +3045 authors, ATLAS Collaboration.
Phys Rev Lett, 2011 Apr 27; 106(12). PMID: 21517301
Beyond sipuleucel-T: immune approaches to treating prostate cancer.
Michael L Cheng, Lawrence Fong.
Curr Treat Options Oncol, 2014 Jan 10; 15(1). PMID: 24402184    Free PMC article.
Review.
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
P Therasse, S G Arbuck, +8 authors, S G Gwyther.
J Natl Cancer Inst, 2000 Feb 03; 92(3). PMID: 10655437
Highly Cited.
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
M F Krummel, J P Allison.
J Exp Med, 1995 Aug 01; 182(2). PMID: 7543139    Free PMC article.
Highly Cited.
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.
Brian Kavanagh, Shaun O'Brien, +6 authors, Lawrence Fong.
Blood, 2008 Jun 05; 112(4). PMID: 18523152    Free PMC article.
Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison.
Science, 1996 Mar 22; 271(5256). PMID: 8596936
Highly Cited.
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Ravi A Madan, Mahsa Mohebtash, +10 authors, James L Gulley.
Lancet Oncol, 2012 Feb 14; 13(5). PMID: 22326924    Free PMC article.
Highly Cited.
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
G J Bubley, M Carducci, +22 authors, G Wilding.
J Clin Oncol, 1999 Nov 05; 17(11). PMID: 10550143
Highly Cited.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.
Lukas Baitsch, Petra Baumgaertner, +9 authors, Daniel E Speiser.
J Clin Invest, 2011 May 11; 121(6). PMID: 21555851    Free PMC article.
Highly Cited.
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
F Stephen Hodi, Sandra Lee, +7 authors, John M Kirkwood.
JAMA, 2014 Nov 05; 312(17). PMID: 25369488    Free PMC article.
Highly Cited.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
B Harpreet Singh, James L Gulley.
Asian J Androl, 2014 Jan 18; 16(3). PMID: 24435055    Free PMC article.
Review.
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
Lawrence Fong, Serena S Kwek, +8 authors, Eric J Small.
Cancer Res, 2009 Jan 17; 69(2). PMID: 19147575
Highly Cited.
CTLA-4 can function as a negative regulator of T cell activation.
T L Walunas, D J Lenschow, +5 authors, J A Bluestone.
Immunity, 1994 Aug 01; 1(5). PMID: 7882171
Highly Cited.
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.
Peter A Prieto, James C Yang, +6 authors, Giao Q Phan.
Clin Cancer Res, 2012 Jan 25; 18(7). PMID: 22271879    Free PMC article.
Highly Cited.
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.
Caroline Jochems, Jo A Tucker, +6 authors, Jeffrey Schlom.
Cancer Immunol Immunother, 2014 Feb 12; 63(4). PMID: 24514956    Free PMC article.
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.
David McDermott, Celeste Lebbé, +5 authors, Charles M Balch.
Cancer Treat Rev, 2014 Jul 26; 40(9). PMID: 25060490
Highly Cited. Review.
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer.
E D Kwon, A A Hurwitz, +5 authors, J P Allison.
Proc Natl Acad Sci U S A, 1997 Jul 22; 94(15). PMID: 9223321    Free PMC article.
Highly Cited.
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Eugene D Kwon, Charles G Drake, +24 authors, CA184-043 Investigators.
Lancet Oncol, 2014 May 17; 15(7). PMID: 24831977    Free PMC article.
Highly Cited.
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
Geoffrey Y Ku, Jianda Yuan, +7 authors, Jedd D Wolchok.
Cancer, 2010 Feb 10; 116(7). PMID: 20143434    Free PMC article.
Highly Cited.
Immunomodulation: checkpoint blockade etc.
William T Curry, Michael Lim.
Neuro Oncol, 2015 Oct 31; 17 Suppl 7. PMID: 26516223    Free PMC article.
Review.
Regulation of prostate cancer progression by the tumor microenvironment.
Stephen L Shiao, Gina Chia-Yi Chu, Leland W K Chung.
Cancer Lett, 2016 Feb 02; 380(1). PMID: 26828013    Free PMC article.
Highly Cited. Review.
Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.
William T Curry, Ramana Gorrepati, +9 authors, Glenn Dranoff.
Clin Cancer Res, 2016 Feb 14; 22(12). PMID: 26873960    Free PMC article.
GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses.
Serena S Kwek, James Kahn, +8 authors, Lynn E Spitler.
Oncoimmunology, 2016 May 04; 5(4). PMID: 27141383    Free PMC article.
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements.
Pierre-Olivier Gaudreau, John Stagg, Denis Soulières, Fred Saad.
Biomark Cancer, 2016 May 12; 8(Suppl 2). PMID: 27168728    Free PMC article.
Review.
Immune checkpoint blockade therapy for bladder cancer treatment.
Jayoung Kim.
Investig Clin Urol, 2016 Jun 22; 57 Suppl 1. PMID: 27326412    Free PMC article.
Review.
Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank.
Ashish M Kamat, Piyush Agarwal, +12 authors, Jonathan E Rosenberg.
Bladder Cancer, 2016 Jul 05; 2(2). PMID: 27376139    Free PMC article.
Immunotherapy in genitourinary malignancies.
Max M Wattenberg, Lawrence Fong, Ravi A Madan, James L Gulley.
Curr Opin Urol, 2016 Jul 30; 26(6). PMID: 27471994    Free PMC article.
Review.
Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment.
Patrick H Lizotte, Robert E Jones, +12 authors, Kwok-Kin Wong.
Sci Rep, 2016 Aug 20; 6. PMID: 27539742    Free PMC article.
Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.
Xiao X Wei, Stephen Chan, +13 authors, Lawrence Fong.
Cancer Immunol Res, 2016 Nov 03; 4(11). PMID: 27688020    Free PMC article.
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
Sumit K Subudhi, Ana Aparicio, +14 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2016 Oct 30; 113(42). PMID: 27698113    Free PMC article.
Highly Cited.
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
David Y Oh, Jason Cham, +5 authors, Lawrence Fong.
Cancer Res, 2016 Dec 30; 77(6). PMID: 28031229    Free PMC article.
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.
Lupe G Salazar, Hailing Lu, +7 authors, Mary L Disis.
JAMA Oncol, 2017 Jan 24; 3(7). PMID: 28114604    Free PMC article.
Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients.
Luc Cabel, Elika Loir, +6 authors, Karim Fizazi.
J Immunother Cancer, 2017 Apr 22; 5. PMID: 28428880    Free PMC article.
Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice.
Ronald Anderson, Bernardo L Rapoport.
Front Oncol, 2018 Apr 07; 8. PMID: 29623257    Free PMC article.
Review.
Comparisons of therapeutic efficacy and safety of ipilimumab plus GM-CSF versus ipilimumab alone in patients with cancer: a meta-analysis of outcomes.
Peng Chen, Fuchao Chen, Benhong Zhou.
Drug Des Devel Ther, 2018 Jul 18; 12. PMID: 30013322    Free PMC article.
Immunotherapy for Brain Tumors.
Lan B Hoang-Minh, Duane A Mitchell.
Curr Treat Options Oncol, 2018 Oct 13; 19(11). PMID: 30311004
Review.
How Prostate Cancer Cells Use Strategy Instead of Brute Force to Achieve Metastasis.
Darron Tharp, Srinivas Nandana.
Cancers (Basel), 2019 Dec 11; 11(12). PMID: 31817000    Free PMC article.
Review.
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.
Qingyang Xiao, André Nobre, +5 authors, Isabel Barragán.
J Clin Med, 2020 Jan 24; 9(1). PMID: 31968651    Free PMC article.
Review.
Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised.
A Charlotte M T de Wolf, Carla A Herberts, Marcel H N Hoefnagel.
Front Med (Lausanne), 2020 Apr 18; 7. PMID: 32300597    Free PMC article.
Systematic Review.
Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.
Jason Cham, Li Zhang, +5 authors, Lawrence Fong.
J Immunother Cancer, 2020 May 08; 8(1). PMID: 32376721    Free PMC article.
Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy.
Julie N Graff, Mark N Stein, +8 authors, Tomasz M Beer.
Front Oncol, 2020 Aug 28; 10. PMID: 32850444    Free PMC article.
Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
Andrew L Laccetti, Sumit K Subudhi.
Curr Opin Urol, 2017 Aug 22; 27(6). PMID: 28825923    Free PMC article.
Review.
Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis.
Kelcie Witges, Leigh Anne Shafer, +4 authors, Charles N Bernstein.
Drug Saf, 2020 Aug 05; 43(12). PMID: 32749630
Systematic Review.
Tumor morphology and location associate with immune cell composition in pleomorphic sarcoma.
Rosanna L Wustrack, Evans Shao, +7 authors, Ross A Okimoto.
Cancer Immunol Immunother, 2021 Apr 18; 70(10). PMID: 33864502    Free PMC article.
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.
Karim Fizazi, Charles G Drake, +23 authors, CA184-043, Investigators.
Eur Urol, 2020 Aug 20; 78(6). PMID: 32811715    Free PMC article.
Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy.
Wenxiang Zhang, Xiangyi Kong, +6 authors, Jing Wang.
Front Oncol, 2021 Oct 12; 11. PMID: 34631507    Free PMC article.
Review.
Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness.
Daniel Hirschhorn, Allison Betof Warner, +11 authors, Jedd D Wolchok.
JCI Insight, 2021 Oct 23; 6(20). PMID: 34676831    Free PMC article.
Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei.
Kjersti Flatmark, Annette Torgunrud, +5 authors, Else Marit Inderberg.
J Immunother Cancer, 2021 Oct 30; 9(10). PMID: 34711663    Free PMC article.
Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox.
David Y Oh, Lawrence Fong.
Immunity, 2021 Dec 16; 54(12). PMID: 34910940    Free PMC article.
Review.
Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy.
Nasrin Aktar, Chen Yueting, +7 authors, Xiaohui Zhou.
J Oncol, 2022 Apr 12; 2022. PMID: 35401745    Free PMC article.
Review.